Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We found that 8 of 10 patients with aplastic anemia experienced resolution of platelet transfusion refractoriness following daratumumab administration. Notably, 4 responders achieved hematopoietic recovery, including 3 participants who showed improvements in multilineage blood cell counts, even with daratumumab monotherapy. This trial was registered at www.clinicaltrials.gov as #NCT05832216.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood.2025029006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic Value of C-Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma.
Hematol Oncol
September 2025
Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Previous studies have shown that the pre-transplant C-reactive protein (CRP)/platelet ratio (CP ratio) is a predictor of survival. The aim of this multicenter retrospective study was to evaluate the clinical significance of CP ratio in patients with malignant lymphoma (ML) who underwent allogeneic hematopoietic stem cell transplantation (alloHCT). The cohort included patients with ML who underwent first alloHCT from 2007 to 2021.
View Article and Find Full Text PDFPathogen reduction diminishes the protective effects of platelets on endothelial barrier permeability in vitro.
Blood Vessel Thromb Hemost
August 2025
Department of Laboratory Medicine, University of California, San Francisco, CA.
Platelet transfusion not only attenuates bleeding and promotes hemostasis but also plays a critical role in vascular stability and endothelial barrier integrity. Under amotosalen-UVA pathogen reduction of platelets, pathogen nucleic acids undergo adduction, which prevents their replication and greatly reduces the risk of transfusion-transmitted infections. Although pathogen-reduced (PR) platelets are increasing in clinical use, the physiologic effects of pathogen reduction on platelets, particularly its impact on platelet-endothelial interactions, have yet to be described.
View Article and Find Full Text PDFCYP2C19 Genetic Variants Associated with Clopidogrel Resistance and Major Adverse Cardiovascular Events in Vietnamese Patients Undergoing Percutaneous Coronary Intervention.
Cardiovasc Hematol Disord Drug Targets
August 2025
Institute of Pharmacy Training, Vietnam Military Medical University, Hanoi, Vietnam.
Introduction: Acute coronary syndrome (ACS) is a leading cause of death, and clopidogrel resistance remains a major challenge in its treatment. This study aims to determine the impact of CYP2C19 genetic variants on clopidogrel resistance (CR) and major adverse cardiovascular events (MACEs) in Vietnamese patients undergoing percutaneous coronary intervention (PCI).
Methods: We carried out a descriptive cross-sectional study, supplemented by a prospective longitudinal follow-up, on 113 ACS patients undergoing PCI with drug-eluting stent implantation at the Department of Cardiology, Military Hospital 103, from January 2015 to May 2018.
Integrin β3 dysregulation impairs megakaryopoiesis and microparticle production via disrupting ROCK-dependent cytoskeletal dynamics.
J Thromb Haemost
September 2025
Key Laboratory of Thrombosis and Hemostasis of National Health Commission, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China; Engineering Center of Hematological Disease of Ministry of Education, Cyrus Tang Hematology Center, Collaborative Innovation
Background: Megakaryocyte (MK) fragmentation into proplatelets (PPTs) and microparticles (MKMPs) is well established, yet the mechanisms underlying MKMP generation remain unclear.
Objectives: In order to investigate the role of integrin β3 and cytoskeletal dynamics during megakaryopoiesis and explore potential therapeutic targets for thrombocytopenia.
Methods: Proplatelet formation and MKMP release were evaluated both in vivo and in vitro under integrin β3 receptor impaired environment.
Relieving platelet inhibition using a novel bi-specific antibody: A novel approach for circumventing the platelet storage lesion.
J Thromb Haemost
September 2025
Blood Research Institute, Versiti, Milwaukee, WI; Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI; Department of Cell biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, WI. Electronic address:
Background: Human platelets experience structural and functional deterioration during extra-corporeal storage at either room temperature or in the cold, impairing their reactivity and diminishing their hemostatic effectiveness following transfusion. PECAM-1 is an inhibitory receptor on platelets that exerts its inhibitory effects via phosphorylation of tyrosine residues that lie within its cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The purpose of this investigation was to attempt to restore platelet reactivity by impairing the inhibitory activity of PECAM-1.
View Article and Find Full Text PDF